Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
US11629188B2 · kind B2 · utility
0Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 27, 2020 |
| Grant date | Apr 18, 2023 |
| Priority date | — |
| Expiry date | Jul 4, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.